Results 91 to 100 of about 16,591 (206)

Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines [PDF]

, 2019
An increasingly recognized mechanism of prostate cancer resistance is the transdifferentiation from adenocarcinoma to treatment-emergent neuroendocrine prostate cancer (t-NEPC), an extremely aggressive malignancy.
Ci, Xinpei, Clermont, Pier-Luc, Crea, Francesco, Pandha, Hardev, Wang, Yuzhuo   +4 more
core   +1 more source

Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy

Cancer Science, EarlyView.
Early screening for somatic alterations in localized prostate cancer could help predict biochemical recurrence risk and optimize salvage therapy selection. ABSTRACT The clinical significance of comprehensive genomic profiling (CGP) has been established in metastatic castration‐resistant prostate cancer (PC).
Kenji Zennami, Tetsuya Takimoto, Takuhisa Nukaya, Makoto Sumitomo, Mayu Takeda, Eiji Sugihara, Hideyuki Saya, Ryoichi Shiroki   +7 more
wiley   +1 more source

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population

Cancer Management and Research, 2011
Nicole M Engel-Nitz1, Berhanu Alemayehu2, David Parry3, Faith Nathan21Innovus, Eden Prairie, MN, USA; 2AstraZeneca, Wilmington, DE, USA; 3AstraZeneca UK, London, UKObjective: Differences in treatment patterns, health care resource utilization, and costs ...
Engel-Nitz NM, Alemayehu B, Parry D, Nathan F   +3 more
doaj  

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review [PDF]

, 2017
Background: Prostate cancer can be treated with several different modalities, including radiation treatment. Various prognostic tools have been developed to aid decision making by providing estimates of the probability of different outcomes.
Beckmann, K., Borg, M., Campbell, J., Evans, S., McNeil, J., Millar, J., Moretti, K., O'Callaghan, M., Raymond, E., Roder, D., Vincent, A., Zalcberg, J.   +11 more
core   +3 more sources

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Human Adipose Stem Cells Engineered to Express Carboxylesterase Confer Anti-Tumoral Efficacy of Irinotecan in Castration-Resistant Prostate Cancer Bone Metastasis Growth and Osteolysis

The World Journal of Men's Health
Purpose: Castration-resistant prostate cancer (CRPC) presents a significant clinical challenge, particularly when it metastasizes to bone, leading to skeletal-related events such as osteolysis.
Da Hyun Yun, Jae Heon Kim, Sang Hun Lee, Eun Jung Lee, Serk In Park, Yun Seob Song   +5 more
doaj   +1 more source

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study

The Prostate, Volume 86, Issue 5, Page 599-608, April 2026.
ABSTRACT Introduction In real‐world practice in Japan, standard treatment for metastatic hormone‐naïve prostate cancer (mHNPC) is androgen deprivation therapy (ADT), administered as monotherapy, combined androgen blockade (CAB), ADT plus androgen receptor pathway inhibitors (ARPIs), or ADT plus docetaxel.
Atsushi Mizokami, Rikiya Matsumoto, Hideaki Miyake, Hiroji Uemura, Hirotsugu Uemura, Satoru Kawakami, Kazuyoshi Nakamura, Shigekatsu Maekawa, Hiroaki Tsuchiya, Sachie Okazaki, Eri Adachi, Ryo Yano, Yohei Tajima, Kiyohide Fujimoto, Hideyasu Matsuyama   +14 more
wiley   +1 more source

Post‐Therapeutic Dosimetry of Metastatic Castration‐Resistant Prostate Cancer With 177Lu‐PSMA: Experiences From Two University‐Based Hospitals in Thailand

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 199-206, April 2026.
ABSTRACT Objective 177Lu‐PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration‐resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu‐PSMA‐RLT from two university ...
Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon‐iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee   +6 more
wiley   +1 more source

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage

Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.
ABSTRACT Inactivation of cyclin‐dependent kinase 12 (CDK12) characterizes a subset of prostate cancers but it is not understood how cells adapt to declining activity of this major transcription elongation kinase. To probe this response, we developed a cell line resistant to an inhibitor targeting CDK12 and its paralog, CDK13.
Aishwarya Gondane, Shivani Yalala, Jing Liang, Sonja Saira, Harri M. Itkonen   +4 more
wiley   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source